GSMA
25.2.2020 13:02:04 CET | Business Wire | Press release
The GSMA today announced winners of the 2020 Global Mobile (GLOMO) Awards. The GLOMOs showcase those companies and individuals that are driving innovation in the rapidly evolving mobile industry.
“Our congratulations to all of the winners and nominees of the GSMA’s GLOMO Awards 2020,” said John Hoffman, CEO, GSMA Ltd. “The GLOMOs are a testament to the incredible innovation and ingenuity shaping our industry and it is truly an outstanding achievement to have been selected by our esteemed judging panels. We thank all of our entrants, judges, sponsors and partners for supporting the 2020 GLOMOs.”
The winners of the 2020 GLOMO Awards are:
Best Mobile Network Infrastructure
Vodafone, Parallel Wireless and Telecom Infra Project for Global OpenRAN Deployments
Best Mobile Technology Breakthrough (Companies > $10million Annual Global Revenue)
Ericsson for Ericsson Spectrum Sharing (ESS)
Best Mobile Technology Breakthrough (Companies < $10million Annual Global Revenue)
KaiOS for KaiOS, Enable Tomorrow
Best Network Software Breakthrough (Companies > $10million Annual Global Revenue)
Parallel Wireless for OpenRAN Controller and Network Software
Best Network Software Breakthrough (Companies < $10million Annual Global Revenue)
Cohere Technologies for Improved 4G and 5G FDD/TDD Networks
Best Mobile Authentication & Security Solution
Nuance Communications Inc. for Nuance Gatekeeper
5G Leadership Award
Huawei for Gear up with Huawei’s E2E 5G Products
5G Industry Partnership Award
China Unicom, BMW & Huawei for 5G Digital Factory Enable Automobile Manufacturing Digital Transformation
Outstanding Mobile Technology Award
Ericsson for Ericsson Spectrum Sharing (ESS)
Best Mobile Operator Service for Consumers
Vimplecom for Beeline & Liza Alert
Best Mobile service for the Connected Life
CalAmp for Here Comes The Bus
Most Innovative Mobile App
Turkcell for BiP Translate
Best Mobile Innovation for Work
China Eastern Airlines, China Unicom & Huawei for 5G Smart Travel in Airport
Best Mobile Innovation for Health and Biotech
Flare for World-Class Emergency Response Technologies
Best Mobile Innovation for Automotive
SK Telecom for Smart Fleet: Data Analytics Platform for Intelligent Mobility
Best Mobile Innovation for Payment and FinTech
Juvo for Financial Identity as a Service (FiDaaS)
Best Mobile Innovation for Smart Cities
China Mobile Group Zhejiang and Huawei for NB-IoT Smart City Fire Control
Best Mobile Innovation for Media and Entertainment
LG Uplus for U+VR 5G
Best Mobile Innovation for Building Trust in the Digital Age
Samsung Electronics for Knox Security Platform
Tech of the Future Award
Huawei for Atlas 900 AI Cluster - The Pinnacle of AI Compute for Future Inclusion
Best Smartphone
OnePlus for OnePlus 7T Pro
Disruptive Device Innovation Award
Qualcomm for Qualcomm Snapdragon X55 5G modem
Best Connected Consumer Device
Vasco Electronics for Vasco Mini2
Best Mobile Innovation for Emerging Markets
Safaricom for DigiFarm
Best Mobile Innovation supporting Emergency or Humanitarian Situations
MapSwipe for Missing Maps
Best Mobile Innovation for Accessibility & Inclusion
SK Telecom for Driving Assistance Solution for Hearing-Impaired Taxi Driver
Best Mobile Innovation for Climate Action
Huawei for Huawei PowerStar™ Solution, 3-Level AI-Based Energy Saving solution
Best Mobile Initiative for Enhancing Children’s Lives
Accenture for SAATHI – Autism Therapy at your Fingertips
Outstanding Mobile Contribution to the UN SDGs
KT for Global Epidemic Prevention Platform
Government Leadership Award
The Government of the Kingdom of Saudi Arabia
Outstanding Contribution to the Mobile Industry
Safaricom
Women4Technology – Industry Leadership Award
Elena Sinel, Founder for Teens In AI
Diversity in Tech Award
Teens In AI for Teens In AI
25 Years of Connecting People Award
Dr Mike Short - A constant champion of the role of mobile technology for the enhancement of society
YoMo STEAM Activity for Children Award
SK Telecom for Happy Coding School for Adolescents with Special Needs
For further information on GLOMO Awards winners please visit https://www.globalmobileawards.com/
- ENDS-
About the GSMA
The GSMA represents the interests of mobile operators worldwide, uniting more than 750 operators and nearly 400 companies in the broader mobile ecosystem, including handset and device makers, software companies, equipment providers and internet companies, as well as organisations in adjacent industry sectors. The GSMA also produces the industry-leading MWC events held annually in Barcelona, Los Angeles and Shanghai, as well as the Mobile 360 Series of regional conferences.
For more information, please visit the GSMA corporate website at www.gsma.com . Follow the GSMA on Twitter: @GSMA.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200225005494/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom